Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study

Publication: Research - peer-reviewJournal article

Standard

Clopidogrel paclitaxel drug-drug interaction : A pharmacoepidemiologic study. / Agergaard, K; Mau-Sørensen, M; Stage, T B; Jørgensen, T L; Hassel, R E; Dahl Steffensen, Karina; Pedersen, J W; Milo, M L H; Poulsen, S H; Pottegård, A; Hallas, J; Brøsen, K; Bergmann, T K.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. Renal Therapy, 2017, p. 547–553.

Publication: Research - peer-reviewJournal article

Harvard

APA

Vancouver

Author

Agergaard, K; Mau-Sørensen, M; Stage, T B; Jørgensen, T L; Hassel, R E; Dahl Steffensen, Karina; Pedersen, J W; Milo, M L H; Poulsen, S H; Pottegård, A; Hallas, J; Brøsen, K; Bergmann, T K / Clopidogrel paclitaxel drug-drug interaction : A pharmacoepidemiologic study.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. Renal Therapy, 2017, p. 547–553.

Publication: Research - peer-reviewJournal article

Bibtex

@article{ef14cdd6ea0a4a5b87f9b18e6fef5e91,
title = "Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study",
abstract = "Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age and sex matched controls treated with paclitaxel and low dose aspirin. By a cumulative dose of 1500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% CI, 0.9-3.0). Among those receiving a high dose paclitaxel regimen, the hazard ratio was 2.3 (95% CI, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high dose paclitaxel. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "K Agergaard and M Mau-Sørensen and Stage, {T B} and Jørgensen, {T L} and Hassel, {R E} and {Dahl Steffensen}, Karina and Pedersen, {J W} and Milo, {M L H} and Poulsen, {S H} and A Pottegård and J Hallas and K Brøsen and Bergmann, {T K}",
note = "© 2017 American Society for Clinical Pharmacology and Therapeutics.",
year = "2017",
doi = "10.1002/cpt.674",
volume = "102",
pages = "547–553",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "JohnWiley & Sons, Inc.",
number = "Renal Therapy",

}

RIS

TY - JOUR

T1 - Clopidogrel paclitaxel drug-drug interaction

T2 - Clinical Pharmacology and Therapeutics

AU - Agergaard,K

AU - Mau-Sørensen,M

AU - Stage,T B

AU - Jørgensen,T L

AU - Hassel,R E

AU - Dahl Steffensen,Karina

AU - Pedersen,J W

AU - Milo,M L H

AU - Poulsen,S H

AU - Pottegård,A

AU - Hallas,J

AU - Brøsen,K

AU - Bergmann,T K

N1 - © 2017 American Society for Clinical Pharmacology and Therapeutics.

PY - 2017

Y1 - 2017

N2 - Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age and sex matched controls treated with paclitaxel and low dose aspirin. By a cumulative dose of 1500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% CI, 0.9-3.0). Among those receiving a high dose paclitaxel regimen, the hazard ratio was 2.3 (95% CI, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high dose paclitaxel. This article is protected by copyright. All rights reserved.

AB - Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age and sex matched controls treated with paclitaxel and low dose aspirin. By a cumulative dose of 1500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% CI, 0.9-3.0). Among those receiving a high dose paclitaxel regimen, the hazard ratio was 2.3 (95% CI, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high dose paclitaxel. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1002/cpt.674

DO - 10.1002/cpt.674

M3 - Journal article

VL - 102

SP - 547

EP - 553

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - Renal Therapy

ER -